Navigation Links
Genprex Announces New Patent Issuance in Japan
Date:10/18/2011

AUSTIN, Texas, Oct. 18, 2011 /PRNewswire/ -- A new patent covering tumor suppression technologies, including the company's lead product candidate Oncoprex™, was recently awarded to The University of Texas System by the Japan Patent Office. Patent number 4813746 pertains to the discovery that chromosome 3p21.3 genes act as cancer suppressors. The family of tumor suppressors include TUSC2, also known as FUS1, the anti-cancer agent in Oncoprex therapy which is undergoing clinical evaluation for lung cancer patients in the U.S.

"Japan represents an important clinical population," stated Chief Operating and Financial Officer Greg Heinlein. "We intend to include Japanese collaborators in our development and commercialization plans and have begun to establish key relations within the region, including appointments of leading oncology experts to our Medical and Scientific Advisory Board."

Genprex controls a portfolio of biomedical technologies including targeted molecular therapeutics for cancer and other diseases. The novel technologies, including those licensed exclusively from The University of Texas MD Anderson Cancer Center, are protected by 15 issued patents and 9 pending applications in major market areas. These broadly applicable technologies have been the subject of more than 20 peer-reviewed scientific publications in the fields of cancer, genomics and molecular biology.

About Oncoprex™Oncoprex is a nanomolecular therapy harnessing the TUSC2 tumor suppressor. TUSC2 defects are associated with most major cancers and >85% of lung cancers. Intravenous Oncoprex induces apoptosis or programmed cell death in cancer cells and controls cell signaling and inflammation to fight cancer along universal cancer pathways. In phase I clinical testing of Stage IV lung cancer patients, Oncoprex monotherapy was well tolerated and demonstrated clinically significant anti-cancer activity in primary lung tumors and metastatic tumors, including liver and pancreas. A phase II clinical trial evaluating Oncoprex in combination with Tarceva® (erlotinib) is planned for 2012. The trial will enroll lung cancer patients without the EGFR mutation and patients with EGFR mutations who have become unresponsive to erlotinib.

About GenprexGenprex, Inc. is a privately held, clinical-stage biopharmaceutical company developing nanomolecular therapies that control universal cancer pathways to unlock the unrealized potential of a variety of targeted cancer therapies. For more information about Genprex click here. Tarceva® is a registered trademark of the Roche Group, including Genentech and Chugai, and of Astellas Pharma.Contact:

Greg HeinleinPhone:

512-597-5900www.genprex.com
'/>"/>

SOURCE Genprex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. SomaLogic Announces Research Agreement with Leading Global Pharmaceutical Company to Accelerate Pharmaceutical Discovery and Development
2. Rock Creek Pharmaceuticals Announces Expanded International Shipping Options for Anatabloc™, Physician Conferences on Anatabine Research
3. Hologic Announces Jury Verdict in Patent Infringement Suit
4. Regeneron Pharmaceuticals Announces Pricing of Offering of Convertible Senior Notes due October 1, 2016
5. Aethlon Medical Announces Availability of its Exosome Detection Assay to the Research Community
6. Hospira Announces Certain Preliminary Third-Quarter 2011 Results
7. Ampio Pharmaceuticals Announces a Proof of Concept Trial of Danazol in the Treatment of Allergic Rhinitis Supports Mechanism of Action of Optina™
8. Bend Research Announces Schedule of Events at 2011 AAPS Annual Meeting and Exposition
9. Pacira Pharmaceuticals, Inc. Announces Key EXPAREL™ Data to be Presented at American College of Surgeons 97th Annual Clinical Congress
10. Halozyme Announces Positive Results from Roches Subcutaneous Herceptin Phase 3 Trial
11. Express Scripts Announces Third Quarter 2011 Earnings Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... OAKLAND, N.J. , June 24, 2016 /PRNewswire/ ... in the design, development and manufacturing of collagen ... and regeneration announced today that Bill Messer ... Sales and Marketing to further leverage the growing ... surgery medical devices. Bill joins the ...
(Date:6/24/2016)... , June 24, 2016 ... the "Structural Electronics 2015-2025: Applications, Technologies, Forecasts" ... In-Mold Electronics, Smart Skin, Structural ... Structural electronics involves electronic and/or ... protective structures, replacing dumb structures such as vehicle ...
(Date:6/24/2016)... Research and Markets has announced the addition of the ... to their offering. ... World Market for Companion Diagnostics covers the world market for ... report includes the following: , World IVD ... (N. America, EU, ROW), 2015-2020 , World IVD Companion ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... ... PawPaws brand pet supplements owned by Whole Health Supply is ... of felines. The formula is all-natural and is made from Chinese herbs that have ... Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root Extract ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... ... fertility once they have been diagnosed with endometriosis. These women need a treatment ... also require a comprehensive approach that can help for preservation of fertility and ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Austin residents ... the American College of Mohs Surgery and to Dr. Russell Peckham for medical and ... highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed ...
(Date:6/25/2016)... Aliso Viejo, California (PRWEB) , ... June 25, 2016 , ... ... preset to fit their specific project," said Christina Austin - CEO of Pixel Film ... all fully customizable and all within Final Cut Pro X . Simply select ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. ... his M.D from the David Geffen School of Medicine at UCLA. He trained in ... to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he ...
Breaking Medicine News(10 mins):